Dr. Linda Arterburn brings a broad range of biotechnology research and development management experience to Alba Therapeutics. Prior to joining Alba, Dr. Arterburn was Executive Director of Discovery Research at Martek Biosciences. In this capacity, she initiated an inflammation research program and was lead inventor on two patents involving novel anti-inflammatory lipids. She previously led Clinical Research and Scientific Affairs at Martek where she played a key role in the regulatory authorizations for the addition of Martek’s fatty acid products, DHA and ARA, to infant formula in the United States and Canada.  Dr. Arterburn also spent seven years at W.R. Grace & Co., where she led an in vitro toxicology research program, and then served as Manager of Technology and Planning.

 

Dr. Arterburn holds a PhD in Pharmacology and the Molecular Sciences from the Johns Hopkins University School of Medicine, and a Bachelor’s Degree in Biochemistry from the University of Wisconsin.